Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

National seroepidemiological study of COVID‐19 after the initial rollout of vaccines: Before and at the peak of the Omicron‐dominant period in Japan
Takeshi Arashiro, Satoru Arai, Ryo Kinoshita, et al.
Influenza and Other Respiratory Viruses (2023) Vol. 17, Iss. 2
Open Access | Times Cited: 18

Showing 18 citing articles:

Longitudinal analysis of antibody titers after primary and booster mRNA COVID-19 vaccination can identify individuals at risk for breakthrough infection
Hyeongki Park, Naotoshi Nakamura, Shô Miyamoto, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Infection-mediated immune response in SARS-CoV-2 breakthrough infection and implications for next-generation COVID-19 vaccine development
Shô Miyamoto, Tadaki Suzuki
Vaccine (2024) Vol. 42, Iss. 6, pp. 1401-1406
Closed Access | Times Cited: 4
Effectiveness of BA.1- and BA.4/BA.5-containing bivalent COVID-19 mRNA vaccines against symptomatic SARS-CoV-2 infection during the BA.5-dominant period in Japan
Takeshi Arashiro, Yuzo Arima, Jin Kuramochi, et al.
Open Forum Infectious Diseases (2023)
Open Access | Times Cited: 9
Protective effect of previous infection and vaccination against reinfection with BA.5 Omicron subvariant: a nationwide population-based study in Japan
Noriko Kitamura, Kanako Otani, Ryo Kinoshita, et al.
The Lancet Regional Health - Western Pacific (2023) Vol. 41, pp. 100911-100911
Open Access | Times Cited: 9
Characterization of the SARS-CoV-2 antibody landscape in Norway in the late summer of 2022: high seroprevalence in all age groups with patterns of primary Omicron infection in children and hybrid immunity in adults
Gro Tunheim, Even Fossum, Anna Hayman Robertson, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Infection-Induced SARS-CoV-2 Seroprevalence among Blood Donors, Japan, 2022
Ryo Kinoshita, Takeshi Arashiro, Noriko Kitamura, et al.
Emerging infectious diseases (2023) Vol. 29, Iss. 9
Open Access | Times Cited: 7
Bivalent Vaccine Effectiveness Among Adults Aged ≥65 Years During the BA.5-Predominant Period in Japan: The VENUS Study
Wataru Mimura, Chieko Ishiguro, Junko Terada-Hirashima, et al.
Open Forum Infectious Diseases (2023) Vol. 10, Iss. 10
Open Access | Times Cited: 6
Seroprevalence of severe acute respiratory syndrome coronavirus 2 N antibodies between December 2021 and march 2023 in Japan
Seiya Yamayoshi, Etsuko Nagai, Keiko Mitamura, et al.
Epidemiology and Infection (2024) Vol. 152
Open Access | Times Cited: 1
SARS-CoV-2 seroprevalence among healthcare workers in a highly vaccinated Japanese medical center from 2020–2023
Yan Yan, Kanami Ito, Hiroshi Fukuda, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 1
Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence, Japan, 2023
Ryo Kinoshita, Shô Miyamoto, Shoko Sakuraba, et al.
Emerging infectious diseases (2024) Vol. 30, Iss. 6
Open Access | Times Cited: 1
Immune escape and waning immunity of COVID-19 monovalent mRNA vaccines against symptomatic infection with BA.1/BA.2 and BA.5 in Japan
Takeshi Arashiro, Yuzo Arima, Jin Kuramochi, et al.
Vaccine (2023) Vol. 41, Iss. 47, pp. 6969-6979
Open Access | Times Cited: 4
Protective Effect of Previous Infection and Vaccination Against Reinfection with BA.5 Omicron Subvariant: A Nation-Wide Population-Based Study in Japan
Noriko Kitamura, Kanako Otani, Ryo Kinoshita, et al.
(2023)
Closed Access | Times Cited: 3
Saturation time of exposure interval for cross-neutralization response to SARS-CoV-2: Implications for vaccine dose interval
Shô Miyamoto, Yudai Kuroda, Takayuki Kanno, et al.
iScience (2023) Vol. 26, Iss. 5, pp. 106694-106694
Open Access | Times Cited: 2
Clinical Impact of Covid-19 Omicron Variant on Patients in Home Health Care
Katsutoshi Ando, Ayumi Suzuki, Hiroki Yoshida
Home Health Care Management & Practice (2024) Vol. 36, Iss. 4, pp. 326-333
Closed Access
Prevalence of SARS-CoV-2-specific antibodies in a sample of the Lithuanian population-based study in Spring 2023
Martynas Simanavičius, Indrė Kučinskaitė-Kodzė, Snieguolė Kaselienė, et al.
Heliyon (2024) Vol. 10, Iss. 8, pp. e29343-e29343
Open Access
Serum anti-nucleocapsid antibody level induced after primary infection is an immunological surrogate of protection against SARS-CoV-2 re-infection in hybrid immunity holders
Shô Miyamoto, Koki Numakura, Ryo Kinoshita, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Indirect and direct effects of nighttime light on COVID-19 mortality using satellite image mapping approach
Daisuke Yoneoka, Akifumi Eguchi, Shuhei Nomura, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
Estimating serum cross-neutralizing responses to SARS-CoV-2 Omicron sub-lineages elicited by pre-Omicron or Omicron breakthrough infection with exposure interval compensation modeling
Shô Miyamoto, Yudai Kuroda, Takayuki Kanno, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1
Page 1

Scroll to top